BC 007 –
A New Outlook
for Millions
of Patients

Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-coupled receptors. Heart failure and Long Covid belong to this group of diseases. BC 007 can neutralize these autoantibodies and this is why Berlin Cures has developed a product based on scientific knowledge that may help many suffering patients.  

Phase-II-Study & Trial SitesMore Information
About us

Berlin Cures is home to an unrivaled platform technology established around „BC 007“, a novel drug which has the potential to revolutionize the treatment of a number of incurable diseases caused by pathogenic functional autoantibodies (fAABs).

Our missionOur mission is to develop and market a novel pharmaceutical product based on the autoantibody neutralizing potential of our BC 007 platform technology. The goal is to make BC 007 available on the market as fast as possible for patients with Long Covid Syndrome and, in parallel, to successfully complete all clinical studies addressing heart failure.

Our visionOur vision is to become the world market leader for the neutralization of pathogenic functional autoantibodies (AABs). Our research data clearly show that compound BC 007 can help to significantly mitigate or even cure a set of diseases associated with autoantibodies, ranging from Long Covid Syndrome (LCS), Chronic Fatigue Syndrome (ME/CFS), heart failure, and several more.

BC 007 platform technology

Our Technology

The aptamer BC 007 – a non-modified 15mer ssDNA oligonucleotide – is a compound capable of neutralizing functional autoantibodies (AABs) by simple intravenous infusion. It forms the basis of our platform technology and has so far proven to be a safe and effective medication method for autoantibody related diseases.


Long Covid Syndrome (LCS)

Promising compassionate use treatments of patients suffering from Long Covid Syndrome (LCS) in summer 2021 indicated that BC 007 is the only drug worldwide that may cure LCS at the moment. We therefore, aim to make BC 007 available on the market as fast as possible for LCS patients.

More about LCS

Heart Failure

Clinical trials with heart failure patients are far advanced (completion of phase IIa in 2022) and have so far been extremely successful. In fact, all patients treated with BC 007 feel well and show a clear and significant improvement of their heart ejection fraction. After a re-examination of the results to further verify the positive effects of BC 007, it is expected that a broad phase IIb/III study will commence in 2023.

Heart Failure

Test your blood for autoantibodies

Please Note:
Currently, Berlin Cures is getting the Lab prepared for study-related analytic tests. Therefore, effective immediately, Berlin Cures will no longer accept incoming specimens for the measurement of autoantibodies. Please do NOT send us specimens. Thank you for your understanding.

Wir stellen unser Labor um auf kommende Aufgaben, die mit klinischen Studien im Zusammenhang stehen. Daher können wir ab sofort keine Blutproben zur Autoantikörperbestimmung mehr annehmen. Bitte senden Sie uns kein Serum zu. Wir danken für Ihr Verständnis.

Latest News, Stories and Reports

Berlin Cures starts Long COVID Phase II Trial – first patients admitted. Dr. Axel Mescheder appointed Chief Medical Officer.


Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth.

Please use a modern web browser